ABSTRACT. This study aimed to investigate the role of M 3 acetylcholine receptor (M 3 -AChR) expression in airway remodeling. Additionally, we aimed to evaluate the effects of ipratropium bromide solution inhaled in an early phase of asthma on airway remodeling in ovalbumin (OVA)-sensitized and challenged mice. Thirty BALB/c mice were divided into three groups, namely, control group (saline sensitized/challenged mice), asthma group (OVA sensitized/challenged mice), and treatment group (OVA sensitized/challenged mice treated by ipratropium bromide). Pathological changes were detected by histological staining in the bronchopulmonary tissue of mice. WAt/ Pbm (the airway wall area /basement membrane perimeter) ratio of the asthma group (25.37 ± 4.25) increased significantly (P < 0.05) when compared with that of the control (12.89 ± 1.71) and treatment group (15.82 ± 2.91). WAm/Pbm (smooth muscle wall area / basement membrane perimeter) ratio of the asthma group (7.58 ± 2.16) increased significantly (P < 0.05) when compared with that of the control (2.55 ± 0.72) and treatment group (3.36 ± 1.69). M 3 -AChR concentration increased in the treatment group (29.24 ± 3.59) and was significantly different (P < 0.05) from that of the control group (25.50 ± 1.83). During asthma treatment, SAMA can alleviate airway remodeling in murine model by lessening the thickness of bronchial walls and inhibiting the proliferation of smooth muscle cells. There were no obvious changes in M 3 -AChR density in the murine model of asthma characterized by airway remodeling. However, ipratropium bromide may up-regulate the expression of M 3 -AChR in bronchial walls of asthmatic murine model.
INTRODUCTION
Bronchial asthma is a chronic obstructive airway disease that was thought to be entirely reversible. Consequently, asthmatic therapeutic measures have mainly focused on symptomatic control, by alleviating the bronchospasm and reducing airway inflammation (Elias et al., 1999) . However, there is an increasing recognition that long-standing asthma may lead to chronic persistent airflow obstruction regardless of an optimal and timely therapy. This irreversible airflow obstruction is considered an outcome of airway remodeling, which is characterized by structural changes in the bronchial airways. The pathological correlation between M 3 -AChR and airway remodeling and pathogenic mechanisms of this correlation are not entirely clear. Recent attention has been focused on the structural changes that are mentioned to as the characteristics of airway remodeling. Airway remodeling is thought to be a key pathogenic alteration in the asthmatic airway, when compared with the normal airway. There are many typical pathological characteristics of the remodeling response, for example, mucus hypersecretion and metaplasia, subepithelial fibrosis, thickening of the lamina reticularis, myofibroblast hyperplasia, myocyte hyperplasia and hypertrophy, and epithelial hypertrophy in the lungs (Bergeron et al., 2010) . These structural changes are thought to cause irreversible airway obstruction in asthma and airway hyperresponsiveness (Fish and Peters, 1999) . Therefore, it is apparent that investigation of the pathogenesis of airway remodeling should contribute to the prevention and therapy of asthma.
Muscarinic acetylcholine receptors (M-AChRs) are representatives of acetylcholine receptors that form G protein-coupled receptor complexes in cell membranes (Eglen, 2006) . Five muscarinic receptor subtypes have been determined by using selective radioactively labeled agonists and antagonists, and are referred to as M 1 -M 5 (Caulfield and Birdsall, 1998) . M 1 -M 4 receptor subtypes have emerged as crucial drug targets for medical treatment of neurological (Thal et al., 2016) , such as schizophrenia and Alzheimer's disease. In human lung tissue, three subtypes of M-AChRs have been identified, including M 1 -AChRs, M 2 -AChRs, and M 3 -AChRs. M 3 -AChRs are located in the airway smooth muscles, submucosal glands, caliciform cells, bronchial epithelial cells, and vascular endothelial cells. M 3 -AChRs help maintain airway tension, stimulate secretion in submucosal glands, and regulate the function of the cholinergic nerve that is closely related to airway smooth muscle tension. A change in M 3 -AChR quantity or function may influence the stability of the lung environment by leading to an imbalance of airway tension and gland secretion.
In 2001, Shen performed radioligand binding assay in lung tissue specimens from patients with chronic obstructive pulmonary disease and found that the number of muscarinic cholinergic receptors was decreased in COPD patients; subtype M 1 and M 3 ratios were increased and subtype M 2 ratio was decreased (Shen et al., 2001) . In 1995, Chang found that M-AChR density was regionally increased in asthmatic guinea pigs, and M-AChR grains in the bronchial/ bronchiolar smooth muscle and bronchial mucosal epithelium were significantly more numerous than in those of the control group (Chang, 1995) . Kistemaker demonstrated that acetylcholine regulates inflammation via M 3 receptors on structural cells (Kistemaker et al., 2015) , and Zhang suggested that bencycloquidium bromide (BCQB; a novel M 3 receptor antagonist) might be used in a potential therapy for inflammation in cigarette smoke-induced pulmonary diseases (Zhang et al., 2015) . Other authors found that M 2 -AChR functions were reduced in asthmatic guinea pigs, mice, rats, and human patients. Although asthmatic patients are known to be hypersensitive to cholinergic agonists, currently no evidence supports the hypothesis that airway smooth muscle contraction mediated by M 3 -AChR is affected by asthma. The aim of this study was to investigate the role of M 3 -AChR expression in the airway and airway remodeling, and to investigate the effect of muscarinic antagonist ipratropium bromide inhaled in an early phase of asthma on allergen-induced airway remodeling in BALB/c mice. The mice were sensitized and challenged with ovalbumin (OVA), and the airway was tested for M 3 -AChR expression.
MATERIAL AND METHODS

Animal models
Thirty 8-week-old female BALB/c mice were procured for the study. The mice (18-22 g) were housed in a conventional room at The Second Hospital of Jilin University, where the research center provided tap water and standard rodent chow diet.
OVA-induced murine asthma model
Thirty female BALB/c mice were divided into three groups (10 per group): control group (group DZ), asthma group (group MX), and treatment group (group YB). The method was modified, based on published literature (Temelkovski et al., 1998; Shen and Wang, 2005; Huang and Qi, 2007) .
Asthma group (MX)
Mice were injected intraperitoneally with 0.2 g/mL OVA solution on days 0, 7, and 14, and challenged by ultrasonic aerosol inhalation of 2.5 g/mL OVA (A5378, Sigma, USA; freshly prepared in saline) solution for 30 min daily from day 15 to 19. They were then challenged every other day from day 20 to 54 with 2.5 g/mL OVA solution to establish the murine model of asthma. As a positive control group, saline was given to the mice by ultrasonic atomization inhalation before challenging.
Treatment group (YB)
Mice were injected intraperitoneally with 0.2 g/mL OVA solution on days 0, 7, and 14, and challenged by ultrasonic aerosol inhalation of 2.5 g/mL OVA solution for 30 min daily from day 15 to 19. They were then challenged every other day from day 20 to 54 with 2.5 g/mL OVA solution. An appropriate dose of ipratropium bromide (Batch No. 709566, Boehringer Ingelheim, Germany) was given to YB mice 20 min before the challenge (100 mg/20 x 25 x 10 cm in volume) to determine whether ipratropium bromide inhibited airway remodeling.
Control group (DZ)
As a negative control group, mice were sensitized and exposed to saline in a similar manner as control. Animals were sacrificed on day 55 after the last challenge.
Histopathology
Lung tissues were fixed in 10% formalin, dehydrated in a graded alcohol series (20, 30, 50, 70, 95%) , cleared with methyl benzoate, embedded in paraffin, and sectioned at 4-5 µm. Slides were stained with hematoxylin and eosin (H&E; Batch No. C-0021, Bioss, China) to detect airway remodeling. Airway remodeling was evaluated by H&E staining of small bronchial wall thickening.
For each slide that was observed under an optical microscope (400X magnification; OLYMPUS BX50, Japan), we selected three whole cross sections of small bronchi with an average diameter of 50-200 mm. We then measured and calculated the basement membrane perimeter (Pbm), airway wall area (WAt), and smooth muscle wall area (WAm) using an image analysis system (Xu et al., 2003 ; Image-pro plus 6.0, Media Cybernetics, USA).
Immunohistochemical staining
Slides were baked in an electric constant-temperature drying oven for 3 h at 80°C. After a series of procedures, including xylene de-waxing, gradient ethanol hydration, and tap water washing, slides were incubated in 3% hydrogen peroxide solution for 10 min at ambient temperature, and blocked in 10% animal serum for 1-2 h. These slides were incubated with rabbit anti-mouse M 3 acetylcholine receptor antibodies (Batch No. bs-1289R, Bioss, P.R. China) at 1:100 dilution, at 4°C overnight, washed three times with phosphate buffer saline, and then incubated with sheep anti-rabbit polyclonal antibodies (Batch No. KIT-9720, MaixinBio, P.R. China) at 1:1000 dilution, at 37°C, for 10 min. Color reactions were developed by incubating with diaminobenzidine and counterstaining with hematoxylin. Controls were obtained by replacing the primary antibodies with PBS.
For each slide that was observed (400X magnification) under the optical microscope, we selected three whole cross sections of small bronchi with an average diameter of 50-200 mm. We then evaluated M 3 -AChR density in the bronchopulmonary tissue and measured the integral optical density (IOD) values by using an image analysis system (Image-pro plus 6.0, Media Cybernetics, USA).
Statistical analysis
Data are reported as means ± SD. Comparisons of different groups were performed using one-way ANOVA, and SNK q was used for comparisons between two groups, with SPSS 13.0 data analysis and graphing software. P < 0.05 was considered significant.
RESULTS
Histological changes in the lungs of asthmatic mice
Morbid lung tissues undergoing airway remodeling, from asthmatic mice, were histologically examined using H&E staining. The analysis revealed that the small bronchial airways were thickened due to hyperplasia and hypertrophy of smooth muscle cells. Normal lung tissues from the control group (DZ) served as controls ( Figure 1A ). Many obvious cellular infiltrates of inflammatory macrophages, neutrophils, and lymphocytes were seen in the interstitium, along with epithelium damage and mucus metaplasia ( Figure 1B ). Histological changes of lung tissues in the treatment group were considerably reduced ( Figure  1C ) compared with the asthma group. 
Assessment of airway remodeling in asthmatic mice
WAt/Pbm ratio
Compared with the control (12.89 ± 1.71) and treatment group (15.82 ± 2.91), WAt/ Pbm ratio of the asthma group (25.37 ± 4.25) was significantly increased (P < 0.05). No significant differences were observed (P > 0.05) between the treatment group and the control group (Table 1) .
WAm/Pbm ratio
WAm/Pbm ratio of the asthma group (7.58 ± 2.16) significantly increased (P < 0.05) when compared with that of the control (2.55 ± 0.72) and treatment group (3.36 ± 1.69). No significant differences were apparent (P > 0.05) between the treatment group and the control group (Table 1) .
M 3 -AChR expression in small bronchi of mice
Lung tissues from the control (Figure 2A ) and asthma group ( Figure 2B ) were histologically examined using immunohistochemical staining. Tissues stained positive for M 3 -AChR in the bronchial epithelium, bronchial smooth muscle cells, submucosal glands, and goblet cells. M 3 -AChR expression in the small bronchial wall was higher in the treatment group ( Figure 2C ) than in the negative control group (Figure 2A) . 
Quantitation of M 3 -AChR expression in small bronchi of mice
No significant differences (P > 0.05) were noted for M 3 -AChR IOD values in bronchopulmonary tissues between the asthma group (24.72 ± 3.87) and the control group (25.50 ± 1.83). However, M 3 -AChR density increased in the treatment group (29.24 ± 3.59) and was significantly different (P < 0.05) from that in the control group (25.50 ± 1.83; Table 2 ). *P < 0.05; † P > 0.05 vs control group. 
DISCUSSION
Our study found no obvious differences in M 3 -AChR levels in the small bronchial walls of asthmatic mice and the negative control group mice, which was consistent with the literature. We also found that ipratropium bromide could prevent airway remodeling in asthmatic mice. A large number of clinical and laboratory data on asthma have reported that M 2 -AChR dysfunction might have contributed to increased acetylcholine release from parasympathetic nerve endings in the airways (Mirotti et al., 2010) . The enhanced release of ACh due to M 2 -AChR dysfunction led to increased mucus secretion and contraction of airway smooth muscles via M 3 -AChR present in glandular epithelia and airway smooth muscle cells (Rogers, 2001) , leading to induced persistent airway hyperresponsiveness. Ipratropium bromide blocks muscarinic acetylcholine receptors irrespective of their subtypes, resulting in decreased contractility of smooth muscle in the lungs, inhibited mucus secretion and bronchoconstriction, ultimately preventing airway remodeling. Brown found that cholinergic antagonism of muscarinic receptors in human and rat small airways inhibits airway contraction by direct inhibition of contraction through M 3 -AChR, and by M 2 -AChR-mediated inhibition of relaxation (Brown et al., 2013) . Consequently, M 3 -AChR plays an important role in the development of asthmatic airway remodeling. Down-regulation of M 3 -AChR and upregulation of M 2 -AChR in the airway should prevent the development of airway remodeling in patients with asthma.
Currently, the most common types of acetylcholine receptor antagonists are ipratropium bromide and tiotropium bromide. Ipratropium bromide is a quaternary ammonium derivative of atropine that has been found to exert a remarkable bronchodilating effect on asthmatics and chronic bronchitis. It blocks AChRs irrespective of the subtype, and accelerates degradation of cyclic guanosine monophosphate (cGMP), leading to a decrease of intracellular cGMP levels. This is most probably caused by the effect of cGMP on intracellular calcium, resulting in decreased contractility of smooth muscle in the lungs, suppressing mucus secretion and bronchoconstriction. Similarly to ipratropium, tiotropium bromide is a synthetic quaternary anticholinergic drug, rendering it appropriate for once-daily therapy. The pharmacology and clinical safety of tiotropium have been recently reviewed (Gross, 2004) .
Recently, other studies have indicated that long-term use of acetylcholine receptor antagonists affects the number and function of M-AChRs. In 2002, Billington reported that M 3 -AChR levels were increased in the bronchial airways of patients who inhaled ipratropium bromide as a long-term treatment, which increased bronchial hyperresponsiveness (Billington and Penn, 2002) . Similarly, we observed that small bronchial wall M 3 -AChR expression was higher in mice treated with ipratropium bromide than in the negative control group. Kang et al. (2013) found that the expression of M 2 -AChR and M 3 -AChR with age tended to decrease and increase, respectively. Therefore, it is necessary to regulate the dose of acetylcholine receptor antagonists used taking into consideration the number and function of M-AChRs in the lung tissue.
Our data demonstrate that acetylcholine contributes to allergen-induced smooth muscle mass and airway remodeling via M 3 -AChR, and that the level of M 3 -AChR expression in a murine model of chronic asthma can be used to predict bronchial airway remodeling. In conclusion, it is necessary to characterize the expression, functional state, and ratio of the three subtypes of muscarinic receptors in the lung tissue of healthy individuals and asthmatic patients, which would be beneficial for a more informed and effective therapy of respiratory disorders.
